Ranibizumab 100 mg/mL delivered with the Port Delivery System with a 24-week refill rate was noninferior to monthly ranibizumab 0.5 mg injections for the treatment of diabetic macular edema, according to a presenter.
“The Port Delivery System is designed for continuous delivery of ranibizumab,” Arshad M. Khanani, MD, MA, FASRS, said at Angiogenesis, Exudation, and Degeneration 2023. “For diabetic macular edema, it offers a strategy to maintain clinical benefits of monthly intravitreal anti-VEGF therapy while reducing overall treatment burden.”
The phase 3 Pagoda trial